Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...